NDA 022549 · Nova Pneuma
Adasuve
Loxapine · Inhalation
Last checked: Nov 20, 2026Latest source record: Jan 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 21, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
28
5 Phase 3, 0 recruiting
FAERS reports
3,993
3,781 serious, 626 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: BRONCHOSPASM and INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS WARNING: BRONCHOSPASM and INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. ADASUVE can cause bronchospasm that has the potential to lead to respiratory distress and respiratory arrest, particularly in patients with lung diseases ( 4 , 5.1 ) ADASUVE is available only through a restricted program called the ADASUVE REMS ( 5.2 ) Administer ADASUVE only in a certified healthcare setting that has immediate access on site to supplies and healthcare professionals competent in the management of acute bronchospasm and access to emergency assistance for symptoms that require immediate medical attention. Certified healthcare settings must have a short-acting bronchodilator available for the immediate treatment of...
What it is approved for
From the label in effect Oct 1, 2026.
ADASUVE is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults [see Clinical Studies (14) ] . ADASUVE is an atypical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults ( 1 ). Limitations of Use: ADASUVE must be administered only in a certified healthcare setting ( 1 ). Limitations of Use: As part of the ADASUVE REMS Program to mitigate the risk of bronchospasm, ADASUVE must be administered only in a certified healthcare setting [see Warnings and Precautions (5.2) ] .
Mechanism: The mechanism of action of loxapine in the treatment of agitation associated with schizophrenia and bipolar I disorder is unclear. However, its efficacy could be mediated through a combination of antagonism of central serotonin and dopamine receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ADASUVE · LOXAPINE 10MG · POWDER, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Loxapine" as an intervention, any sponsor and status, largest first.
- Staccato Loxapine in Migraine (Out Patient)Pivotal-lookingCompleted
Alexza Pharmaceuticals, Inc.Not stated
NCT00825500 · 366 participants · Start Jan 2009 · Primary completion Aug 2009
Drug: Inhaled Placebo; Inhaled Loxapine 1.25 mg and 1 more · For: Migraine Headache
Sites: Springfield, Missouri; Mount Vernon, New York; East Providence, Rhode Island
- Staccato Loxapine in Agitated Patients With SchizophreniaPivotal-lookingCompleted
Alexza Pharmaceuticals, Inc.Not stated
NCT00628589 · 344 participants · Start Feb 2008 · Primary completion May 2008
Drug: Inhaled loxapine 5 mg; Inhaled loxapine 10 mg and 1 more · For: Patients With Schizophrenia and Acute Agitation
Sites: Atlanta, Georgia
- Staccato Loxapine in Agitated Patients With Bipolar DisorderPivotal-lookingCompleted
Alexza Pharmaceuticals, Inc.Not stated
NCT00721955 · 314 participants · Start Jul 2008 · Primary completion Oct 2008
Drug: Inhaled Placebo; Inhaled loxapine 5 mg and 1 more · For: Bipolar I Disorder
Sites: Escondido, California; Garden Grove, California; Atlanta, Georgia · 6 sites in all
- Haloperidol vs Olanzapine for the Management of ICU DeliriumPivotal-lookingTerminated
Richard HallAcademic, hospital or other
NCT00833300 · 200 participants (planned) · Start Jun 2008 · Primary completion Nov 2011
Drug: Haloperidol; Olanzapine · For: Delirium; Agitation
Sites: Halifax, Canada · 2 sites in all
- Antipsychotic Induced Structural and Functional Brain ChangesPivotal-lookingTerminated
RWTH Aachen UniversityAcademic, hospital or other
NCT02435095 · 174 participants · Start May 2015 · Primary completion Aug 2020
Drug: Maintenance treatment; Intermittent treatment · For: Schizophrenia
Sites: Aachen, Germany; Bonn, Germany; Düren, Germany · 11 sites in all
- Staccato Loxapine in Migraine (in Clinic)Pivotal-lookingCompleted
Alexza Pharmaceuticals, Inc.Not stated
NCT00489476 · 168 participants · Start Jun 2007 · Primary completion Dec 2007
Drug: Staccato Loxapine; Staccato Placebo · For: Migraine
Sites: Wellesley Hills, Massachusetts
- A Study of Staccato Loxapine (ADASUVE®) for InhalationPivotal-lookingStatus unknown
Lee's Pharmaceutical LimitedIndustry
NCT04148963 · 150 participants (planned) · Start Dec 1, 2019 · Primary completion May 1, 2020
Drug: Inhaled loxapine; Inhaled placebo · For: Psychomotor Agitation; Schizophrenia; Bipolar Disorder
- Staccato Loxapine in Agitation (Proof of Concept)Pivotal-lookingCompleted
Alexza Pharmaceuticals, Inc.Not stated
NCT00369577 · 129 participants · Start Aug 2006 · Primary completion Jan 2007
Drug: Inhaled Placebo; Inhaled Loxapine 5 mg and 1 more · For: Schizophrenia
Sites: Upland, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective322
- coma274
- somnolence262
- toxicity to various agents233
- drug interaction225
- weight increased219
- poisoning deliberate215
- off label use202
- suicide attempt185
- akathisia166
- death163
- neuroleptic malignant syndrome159
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 13 |
| 2006 | 27 |
| 2007 | 26 |
| 2008 | 26 |
| 2009 | 20 |
| 2010 | 39 |
| 2011 | 54 |
| 2012 | 41 |
| 2013 | 35 |
| 2014 | 42 |
| 2015 | 81 |
| 2016 | 80 |
| 2017 | 132 |
| 2018 | 168 |
| 2019 | 232 |
| 2020 | 231 |
| 2021 | 276 |
| 2022 | 480 |
| 2023 | 530 |
| 2024 | 577 |
| 2025 | 483 |
| 2026 | 388 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- "Pharmacological management of acute agitation in psychiatric patients: an umbrella review".
Uribe ES, Rodríguez CAB, Juárez MEN, et al. · BMC Psychiatry 2025 · Systematic Review
- Loxapine for schizophrenia.
Chakrabarti A, Bagnall A, Chue P, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Evaluation of amoxapine.
Kinney JL, Evans RL · Clin Pharm 1982 · Clinical Trial, Comparative Study
- Thioridazine for dementia.
Kirchner V, Kelly CA, Harvey RJ · Cochrane Database Syst Rev 2001 · Systematic Review
- New Antipsychotic Medications in the Last Decade.
Pahwa M, Sleem A, Elsayed OH, et al. · Curr Psychiatry Rep 2021 · Systematic Review
- Thioridazine for dementia.
Kirchner V, Kelly C A, Harvey RJ · Cochrane Database Syst Rev 2000 · Systematic Review
Sponsor: Nova Pneuma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.